On January 31, 2024, the Board of Directors of Immunome, Inc. promoted Max Rosett, the Company?s Senior Vice President, Operations and Interim Chief Financial Officer to Executive Vice President, Operations and Interim Chief Financial Officer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.58 USD | -5.27% |
|
-21.38% | +17.57% |
May. 31 | Piper Sandler Initiates Immunome With Overweight Rating, $27 Price Target | MT |
May. 21 | Immunome Insider Bought Shares Worth $1,388,072, According to a Recent SEC Filing | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.57% | 796M | |
+15.85% | 121B | |
+18.91% | 112B | |
+4.43% | 22.57B | |
-18.63% | 20.82B | |
-13.76% | 16.3B | |
-16.61% | 16.19B | |
-43.53% | 16.17B | |
+1.75% | 13.17B | |
+28.07% | 11.11B |
- Stock Market
- Equities
- IMNM Stock
- News Immunome, Inc.
- Immunome, Inc. Announces Promotion of Max Rosett to Executive Vice President, Operations